As founders, we work side-by-side with our entrepreneurs to
build companies around innovative science.
Broadening the reach and
impact of precision medicine
to more people with cancer
Translating epigenetic modulation of oncogenic pathways into first-in-class small molecule therapeutics
Enhancing synaptic integrity for
treatment of neurologic dis-
orders; sold to Alkermes Nov 2019
Rapidly developing new cancer
treatments for people of all ages
– IPO Jun 2021 (NASDAQ: DAWN)
Harnessing the immune system to
defeat cancer with tumor-selective
immunotherapies (NASDAQ: XLO)
Preventing axonal degeneration in
patients with neurological diseases
Sold to Lilly (NYSE: LLY) Oct 2020
Pioneering targeted therapies
for serious muscle diseases –
IPO Sep 2020 (NASDAQ: DYN)
Scalable, re-dosable, non-viral
gene therapy for genetic diseases
IPO Jun 2020 (NASDAQ: GBIO)
Novel bicyclic peptides (bicycles) and
bicycle drug conjugates for cancer
IPO May 2019 (NASDAQ: BCYC)
Novel therapies for severe, highly
drug-resistant bacterial infections
IPO Nov 2017 (NASDAQ: SPRO)
Treating cancer’s toughest
tumors by harnessing the power
of precisely delivered radiation
Novel antibodies built to break
through the tumor microenvironment
IPO Apr 2018 (NASDAQ: SURF)
Targeting the DNA damage
response pathway to prevent and
halt expansion repeat disorders
Next-generation oncolytic immuno-
therapies for cancer treatment
– IPO Jul 2018 (NASDAQ: REPL)
Restoring metabolic balance to treat
NASH and serious metabolic diseases
– IPO Jun 2019 (NADSAQ: AKRO)
Mouse platforms for the generation
of fully human antibodies –
Sold to Harbour BioMed Dec 2016
Advancing novel therapies for people
with rare cardiopulmonary disease
– IPO Jun 2021 (NASDAQ: AVTE)
Novel therapeutics using proprietary
computational chemistry –
Sold to Allergan (NYSE: AGN) Sep 2016
Advancing targeted protein
degradation to target previously
“undruggable” disease pathways
Harnessing the power of microglia to
transform treatments for neuro-
degenerative diseases (NASDAQ: VIGL)
Delivering medicines for rare,
autoimmune, and inflammatory diseases
IPO July 2011 (NASDAQ: HZNP)
Patient-directed oncology therapies
across immune and cancer cell pathways
IPO Mar 2021 (NASDAQ: IKNA)
Breakthrough therapies for neuro-
logical & psychiatric conditions
– Sold to Novartis Dec 2020
Transforming stem cell transplant
therapy for auto-immune and blood-
based diseases (NASDAQ: MGTA)